Core Viewpoint - Suzhou Rebio Technology Co., Ltd. (Rebio) has successfully listed on the Hong Kong Stock Exchange, with its share price closing at HKD 82.10, reflecting a 41.62% increase from the issue price of HKD 57.97 [1][2]. Group 1: Company Overview - Rebio is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1]. - The total number of shares issued in this offering was 31,610,400 H-shares, with 2,748,800 shares allocated for public offering in Hong Kong and 28,861,600 shares for international placement [2]. Group 2: Financial Details - The total proceeds from the offering amounted to HKD 1,832.45 million, with net proceeds of HKD 1,701.80 million after deducting estimated listing expenses of HKD 130.65 million [2][3]. - The funds raised will be allocated to the research and development of core products RBD4059, RBD5044, and RBD1016, as well as to support pipeline assets in preclinical stages and enhance the technology platform [3]. Group 3: Investor Participation - Key cornerstone investors include Arc Avenue Asset Management, Bright Stone Holdings, and several asset management firms, collectively acquiring 42.5% of the offering [6][7]. - The cornerstone investors' total shareholding includes significant contributions from various funds and insurance companies, indicating strong institutional interest in Rebio [6]. Group 4: Financial Performance Projections - For the fiscal years ending December 31, 2023, and December 31, 2024, Rebio is projected to generate revenues of RMB 0.04 million and RMB 142.6 million, respectively, with net losses of RMB 437.3 million and RMB 281.5 million [8]. - The company anticipates a continued trend of net losses in the upcoming periods, with projected losses of RMB 141.6 million for the six months ending June 30, 2025 [8].
瑞博生物港股募18.3亿港元首日涨41.6% 连亏2年半